Transaction DateRecipientSharesTypePriceValue
18th December 2020Jeryl L Hilleman2,500Open or private sale$166.40$416,000.00
16th December 2020Joseph H. Reilly3,228Open or private sale$2.64$8,521.92
14th December 2020Joseph H. Reilly8,750Exercise of derivative$0.00
10th September 2020Heek G Jan Van7,000Open or private purchase$2.97$20,790.00
31st July 2020William F Doyle896Open or private sale$76.39$68,443.65
16th June 2020Jeryl L Hilleman8,797Grant/award etc.$0.00
10th June 2020Jeryl L Hilleman2,541Grant/award etc.$0.00
26th May 2020Frederick W Ahlholm8,339Open or private sale$15.00$125,085.00
11th May 2020William F Doyle31,332Open or private sale$63.73$1,996,725.70
8th May 2020William F Doyle31,903Open or private sale$63.50$2,025,872.40
Minerva Neurosciences
Minerva Neurosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho in 2007.

Ticker: NERV
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1598646
Employees: 13
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Common Stock, Shares, Issued: $41 M (3%)
EPS (basic): $0.75 (0%)
EPS (diluted): $0.73 (0%)